JP2015536953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536953A5 JP2015536953A5 JP2015540873A JP2015540873A JP2015536953A5 JP 2015536953 A5 JP2015536953 A5 JP 2015536953A5 JP 2015540873 A JP2015540873 A JP 2015540873A JP 2015540873 A JP2015540873 A JP 2015540873A JP 2015536953 A5 JP2015536953 A5 JP 2015536953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- composition
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims 8
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000006994 Precancerous Conditions Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100032831 Protein ITPRID2 Human genes 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical group O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 1
- 239000012648 POLY-ICLC Substances 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108700002563 poly ICLC Proteins 0.000 claims 1
- 229940115270 poly iclc Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000002569 water oil cream Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722446P | 2012-11-05 | 2012-11-05 | |
| US61/722,446 | 2012-11-05 | ||
| US201361790780P | 2013-03-15 | 2013-03-15 | |
| US61/790,780 | 2013-03-15 | ||
| PCT/US2013/068582 WO2014071402A1 (en) | 2012-11-05 | 2013-11-05 | Xbp1, cd138, and cs1, pharmaceutical compositions that include the peptides, and methods of using such petides and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018135739A Division JP2018172435A (ja) | 2012-11-05 | 2018-07-19 | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536953A JP2015536953A (ja) | 2015-12-24 |
| JP2015536953A5 true JP2015536953A5 (cg-RX-API-DMAC10.html) | 2016-12-22 |
| JP6374392B2 JP6374392B2 (ja) | 2018-08-15 |
Family
ID=49596483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540873A Active JP6374392B2 (ja) | 2012-11-05 | 2013-11-05 | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| JP2018135739A Withdrawn JP2018172435A (ja) | 2012-11-05 | 2018-07-19 | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| JP2021105587A Active JP7838929B2 (ja) | 2012-11-05 | 2021-06-25 | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018135739A Withdrawn JP2018172435A (ja) | 2012-11-05 | 2018-07-19 | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| JP2021105587A Active JP7838929B2 (ja) | 2012-11-05 | 2021-06-25 | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9950047B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3919069A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP6374392B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110787285B (cg-RX-API-DMAC10.html) |
| AU (4) | AU2013337247B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2888803A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014071402A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2726804C (en) * | 2008-06-02 | 2021-12-28 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20200029627A (ko) | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| EP3936145A1 (en) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| US11338026B2 (en) | 2014-09-10 | 2022-05-24 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| US20170224799A1 (en) * | 2014-09-10 | 2017-08-10 | The University Of Connecticut | Identification of immunologically protective neo-epitopes for the treatment of cancers |
| US10752902B2 (en) | 2014-09-23 | 2020-08-25 | Board Of Trustees Of Michigan State University | Compositions comprising fusion proteins useful for modulating an immune response |
| US20190209669A1 (en) | 2016-08-23 | 2019-07-11 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating breast cancer |
| WO2018039203A1 (en) | 2016-08-23 | 2018-03-01 | Oncopep, Inc. | Peptide vaccines and durvalumab for treating multiple myeloma |
| CA3070468A1 (en) * | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| US12059463B2 (en) * | 2017-10-24 | 2024-08-13 | Oncopep, Inc. | Peptide vaccines and pembrolizumab for treating breast cancer |
| US12590292B2 (en) | 2019-01-07 | 2026-03-31 | Children's National Medical Center | Targeted T-cell therapy for treatment of multiple myeloma |
| EP3941938A1 (en) | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| US11920202B2 (en) | 2020-04-09 | 2024-03-05 | University Of Connecticut | Unbiased identification of tumor rejection mediating neoepitopes |
| US20240285740A1 (en) * | 2021-05-12 | 2024-08-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
| US20250136650A1 (en) * | 2021-11-23 | 2025-05-01 | The University Of Chicago | Compositions and methods for dna binding and transcriptional regulation |
| CN115040663B (zh) * | 2022-06-15 | 2023-12-12 | 上海交通大学医学院附属仁济医院 | 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US185193A (en) | 1876-12-12 | Improvement in wheeled chairs | ||
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (cg-RX-API-DMAC10.html) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| SG44845A1 (en) | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1359937A4 (en) | 2001-02-14 | 2004-07-28 | Genzyme Corp | MODIFIED PEPTIDE LIGANDS |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| WO2005037855A2 (en) | 2003-10-17 | 2005-04-28 | Pecos Labs, Inc. | T cell epitopes useful in a yersinia pestis vaccine and as diagnostic tools and methods for identifying same |
| ES2402184T5 (es) | 2003-12-01 | 2016-10-25 | Sloan-Kettering Institute For Cancer Research | Análogos de péptidos de unión a HLA sintéticos y sus usos |
| PT2301576E (pt) | 2004-03-29 | 2012-12-20 | Abbott Biotherapeutics Corp | Utilização terapêutica de anticorpos anti-cs1 |
| SG171690A1 (en) * | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| US7504225B2 (en) | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20080020979A1 (en) | 2006-06-09 | 2008-01-24 | Rapraeger Alan C | Peptides of Syndecan-1 For Inhibiting Angiogenesis |
| AU2007281682B2 (en) | 2006-08-07 | 2013-05-16 | Abbvie Biotherapeutics Inc. | Compositions and methods using anti-CS1 antibodies to treat multiple myeloma |
| AU2007281684C1 (en) | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| CA2673870A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| CA2726804C (en) | 2008-06-02 | 2021-12-28 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| AU2010248761B2 (en) * | 2009-05-15 | 2016-02-11 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
| WO2012027379A2 (en) * | 2010-08-24 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| JP6374392B2 (ja) | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
-
2013
- 2013-11-05 JP JP2015540873A patent/JP6374392B2/ja active Active
- 2013-11-05 AU AU2013337247A patent/AU2013337247B2/en active Active
- 2013-11-05 EP EP21171538.8A patent/EP3919069A1/en active Pending
- 2013-11-05 CA CA2888803A patent/CA2888803A1/en active Pending
- 2013-11-05 US US14/440,442 patent/US9950047B2/en active Active
- 2013-11-05 CN CN201911000135.7A patent/CN110787285B/zh active Active
- 2013-11-05 EP EP13792561.6A patent/EP2914278B1/en active Active
- 2013-11-05 CN CN201380067770.1A patent/CN105377288B/zh active Active
- 2013-11-05 WO PCT/US2013/068582 patent/WO2014071402A1/en not_active Ceased
-
2017
- 2017-08-29 US US15/689,159 patent/US20180133297A1/en not_active Abandoned
-
2018
- 2018-07-19 JP JP2018135739A patent/JP2018172435A/ja not_active Withdrawn
- 2018-11-08 AU AU2018260912A patent/AU2018260912B2/en active Active
-
2021
- 2021-02-10 US US17/172,805 patent/US12616733B2/en active Active
- 2021-02-26 AU AU2021201265A patent/AU2021201265A1/en not_active Abandoned
- 2021-06-25 JP JP2021105587A patent/JP7838929B2/ja active Active
-
2024
- 2024-08-16 AU AU2024205851A patent/AU2024205851A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1028I2 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1123138T1 (el) | Κυτταροτοξικες πρωτεϊνες που περιλαμβανουν περιοχες δεσμευσης στοχευσης-κυtταρων και περιοχες α υπομοναδας τοξινης shiga για επιλεκτικη θανατωση συγκεκριμενων κυτταρικων τυπων | |
| MX377144B (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
| PE20180693A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer | |
| CY1123906T1 (el) | Αναστολεις απομεθυλασης ιστονης | |
| PE20181316A1 (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer | |
| CN109790222A (zh) | 抗密蛋白18a2的抗体及其应用 | |
| MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
| PE20181490A1 (es) | Tratamientos contra el cancer de utero | |
| PE20231014A1 (es) | Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres | |
| EA201790294A1 (ru) | Средства на основе флагеллина и применения, включающие эффективную вакцинацию | |
| CY1121110T1 (el) | Αντινοηματικα-ολιγονουκλεοτιδια ως παρεμποδιστες σηματοδοτησης tgf-r | |
| EA201000207A1 (ru) | Новые иммуногенные эпитопы для иммунотерапии | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
| JP2016538344A5 (cg-RX-API-DMAC10.html) | ||
| CY1122132T1 (el) | Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| CN109415361A (zh) | 丙烯酸类衍生物及其制备方法和其在医药上的用途 | |
| JP2016531927A5 (cg-RX-API-DMAC10.html) | ||
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza |